NCT06224621View on ClinicalTrials.gov

Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
PROCEDURE

Percutaneous Endocardial Septal Radiofrequency Ablation

Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.

Trial Locations (1)

100037

RECRUITING

Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV